Evidence map›Paper›PMID 26902622›Full record

ReviewCurrent urology reports2016

Female Sexual Dysfunction: Is It a Treatable Disease?

Justin Houman, Tom Feng, Karyn S Eilber, Jennifer T Anger

Abstract readReview
PubMed Publisher
In one paragraph

Review in Current urology reports, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.2field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 9 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Female sexual dysfunction: a focus on flibanserin.International journal of women's health · 2017
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Justin HoumanDepartment of Surgery, Division of Urology, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
Tom FengDepartment of Surgery, Division of Urology, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
Karyn S EilberDepartment of Surgery, Division of Urology, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
Jennifer T AngerDepartment of Surgery, Division of Urology, Cedars-Sinai Medical Center, Los Angeles, CA, USA. angerj@cshs.org.
Cedars-Sinai Medical Center · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Female sexual dysfunction affects approximately 40% of women (Sexual problems and distress in United States women: prevalence and correlates; Shifren et al., Obstet Gynecol, 112(5): 970-978, 2008). Due to its multi-factorial etiology, a wide variety of treatments are available that address specific symptoms, but no treatment exists that treats the overall disorder. Significant strides have recently been made in an effort to treat the plethora of symptoms associated with this disorder. The purpose of this article is to provide an overview of recent research on the available treatments for female sexual dysfunction. We discuss novel agents such as flibanserin, as well as various mechanical devices and hormonal treatments aimed at the specific subtypes of female sexual dysfunction.

Indexed as

BenzimidazolesFemaleHumansPrevalenceSexual BehaviorSexual Dysfunctions, PsychologicalTreatment OutcomeBenzimidazolesflibanserinFemale sexual dysfunctionFemale urologyFlibanserinTreatment

Identifiers

PMID26902622
OpenAlexW2321317630

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.